All In Biotech

Drug Trial Radar · NCT06509906

M9466 in Combination With Topoisomerase 1 Inhibitors-based Regimens in Advanced Solid Tumors and Colorectal Cancer (DDRiver 511)

An Open Label, Multicenter, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of the PARP1 Inhibitor M9466 in Combination With Topoisomerase 1 Inhibitor-based Regimens in Advanced Solid Tumors and Colorectal Cancer (DDRiver 511)

Last checked: Nov 20, 2026Latest source record: Dec 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

3

Actual

Start

Oct 8, 2024

Primary completion

Dec 2, 2025

Study completion Dec 2, 2025

Sponsor

Sponsor type
Industry
Collaborators
Merck KGaA, Darmstadt, Germany
First posted
Jul 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and preliminary clinical activity of M9466 in combination with topoisomerase 1 inhibitors-based regimens. As such the combination with FOLFIRI (folinic acid, fluorouracil, irinotecan) and Bevacizumab will be evaluated in participants with colorectal cancer, to establish the M9466 maximum tolerated dose if observed and the recommended dose for expansion. Study Duration: After a Screening period of up to 28 days, enrolled participants will remain in the study until they have completed all the study visits or until they withdraw consent, are lost to follow-up, or die. Visit Frequency: The participants will come for a Screening Visit and 1 to 2 visits per treatment cycle. After end of study intervention period, the participants will come for an End of Treatment Visit and a Safety Follow-up Visit.

Conditions

  • Advanced Solid Tumor

Interventions

  • M9466Drug

    M9466 will be administered orally until progressive disease, unacceptable toxicity, death, or end of study.

  • IrinotecanDrug

    Irinotecan will be administered intravenously once every 2 weeks (q2w) until progressive disease, unacceptable toxicity, death, or end of study.

  • Folinic acidDrug

    Folinic acid will be administered intravenously q2w as per standard of care.

  • Fluorouracil (5-FU)Drug

    Fluorouracil will be administered intravenously as per standard of care.

  • BevacizumabDrug

    Bevacizumab will be administered intravenously, q2w until progressive disease, unacceptable toxicity, death, or end of study.

  • Granulocyte colony stimulating factor (G-CSF)Drug

    G-CSF will be administered subcutaneously at every cycle of study intervention as per standard of care.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Treatment-Emergent Adverse Events (TEAEs) and Treatment Related TEAEsTime frame: Time from signing Informed Consent Form (ICF) up to 30 days after end of study intervention (approximately assessed up to 18.7 months)
  2. Number of Participants with Dose Limiting Toxicity (DLT)Time frame: Day 1 up to Day 28 of the first two Cycles (each cycle is of 14 days)

Locations

12 sites in 5 countries. Site status is shown where the registry gives one.

  • Sarah Cannon Research Institute at Health One

    Denver, Colorado

  • Carolina BioOncology Institute, LLC - Cancer Therapy and Research Center

    Pennington, New Jersey

  • Vanderbilt University - 150912667

    Nashville, Tennessee

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas

  • Cancer Research SA

    Elizabeth Vale, Australia

  • St George Private Hospital

    Kogarah, Australia

  • Peter MacCallum Cancer Centre - Use the one with Account 2 VCCC

    Parkville, Australia

  • National Cancer Center Hospital

    Chūōku, Japan

  • Samsung Medical Center

    Seoul, South Korea

  • Seoul National University Hospital

    Seoul, South Korea

  • NEXT Barcelona - NEXT Barcelona

    Barcelona, Spain

  • NEXT Madrid - Hospital Universitario Quironsalud Madrid

    Pozuelo de Alarcón, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.